Not a good buy right now for an impatient buyer: trend is still bearish (SMA_200 > SMA_20 > SMA_5) and price is trading below the pivot (11.487), suggesting rallies may face overhead resistance.
Near-term setup is more “catching a falling knife” than a clean reversal: RSI (~38) is weak but not a clear capitulation/oversold bounce signal, and MACD is still negative.
Options imply elevated event risk (very high IV) ahead of earnings on 2026-02-23; that uncertainty does not favor an immediate long entry without a reversal trigger.
Trend: Bearish structure with moving averages stacked down (SMA_200 > SMA_20 > SMA_5), indicating the broader downtrend remains intact.
Momentum: MACD histogram at -0.1 (below zero) and “negatively contracting” = downside momentum is easing, but not yet flipped to bullish.
RSI: RSI_6 at 38.0 = weak/near-oversold zone, but not a definitive reversal signal on its own.
Key levels: Support S1 ~10.772 (near prior close zone) then S2 ~10.33. Resistance at Pivot 11.487, then R1 12.202.
Practical read: A break and hold above 11.487 would be the first technical improvement; losing 10.772 increases downside risk toward ~10.33.
Options Data
Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio
Positioning (Open Interest): Put/Call OI ratio 0.18 (calls heavily outweigh puts) = bullish skew, but can also reflect call overwriting/positioning rather than fresh optimism.
Activity (Volume): Put/Call volume ratio 0.0 and today’s options volume effectively 0 = sentiment signal is weak today (not much real-time confirmation).
Volatility: 30D IV ~126.98 vs historical vol ~42.29, with IV percentile ~96.81 = extremely elevated implied volatility, consistent with major uncertainty/event risk.
Takeaway: Options market is pricing large moves, but today’s lack of volume limits confidence in directional sentiment.
Technical Summary
Sell
7
Buy
4
Positive Catalysts
revenue +5.57% YoY indicates topline growth is still present.
holds.
Neutral/Negative Catalysts
and holds.
Financial Performance
Latest quarter: 2025/Q3.
Revenue: $402.06M, up +5.57% YoY (positive growth).
Profitability: Net income -$5.40M, down -49.47% YoY (worsening losses).
EPS: -$0.07, down -50% YoY (negative trend).
Gross margin: 56.24% (slightly down ~0.05% YoY), indicating no meaningful margin expansion to offset earnings pressure.
Overall: Topline is growing, but earnings quality/trajectory is weakening—this usually caps near-term upside until evidence of margin and EPS stabilization appears.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
No analyst rating/price target change data was provided, so a verified “recent trend” in Street ratings/targets cannot be confirmed from this dataset.
Wall Street-style pros (based on provided fundamentals): revenue growth, upcoming earnings as a potential reset point.
Wall Street-style cons: deteriorating EPS/net income and a bearish technical trend, which often lead to cautious/neutral stances until results improve.
Influential/political trading check: No recent congress trading data available; hedge funds and insiders reported as Neutral with no significant recent trends.
Wall Street analysts forecast IART stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IART is 12.33 USD with a low forecast of 10 USD and a high forecast of 14 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
Wall Street analysts forecast IART stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IART is 12.33 USD with a low forecast of 10 USD and a high forecast of 14 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Buy
2 Hold
4 Sell
Moderate Sell
Current: 10.880
Low
10
Averages
12.33
High
14
Current: 10.880
Low
10
Averages
12.33
High
14
Truist
Hold
downgrade
$15 -> $13
AI Analysis
2025-11-03
Reason
Truist
Price Target
$15 -> $13
AI Analysis
2025-11-03
downgrade
Hold
Reason
Truist lowered the firm's price target on Integra LifeSciences to $13 from $15 and keeps a Hold rating on the shares. The firm notes it was surprised to see a Q3 revenue miss following multiple rebased outlooks, including last quarter. The intra-quarter issues impacted the business and more than overshadowed progress made on profitability and free cash flow, the analyst tells investors in a research note.
JPMorgan
Robbie Marcus
Underweight
maintain
$12 -> $13
2025-10-31
Reason
JPMorgan
Robbie Marcus
Price Target
$12 -> $13
2025-10-31
maintain
Underweight
Reason
JPMorgan analyst Robbie Marcus raised the firm's price target on Integra LifeSciences to $13 from $12 and keeps an Underweight rating on the shares. The firm updated the company's model.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for IART
